**Product Specification Sheet**

**Product Name:** BGJ398 (NVP-BGJ398)  
**Catalog Number:** C6245

### Technical information:

- **Chemical Formula:** C\textsubscript{26}H\textsubscript{31}Cl\textsubscript{2}N\textsubscript{7}O\textsubscript{3}
- **CAS #:** 872511-34-7
- **Molecular Weight:** 560.48
- **Purity:** > 98%
- **Appearance:** white solid
- **Solubility:** Soluble in DMSO up to 1 mM

**Chemical Name:** 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea

**Storage:** For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.

**Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

### Handling:

- To make 10 mM stock solution, add 0.178mL of DMSO for each mg of BGJ398 (NVP-BGJ398).
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

### Biological Activity:

BGJ398 (NVP-BGJ398), discovered in 2011, is a potent pan inhibitor of the fibroblast growth factor receptor (FGF) tyrosine kinases. BGJ398 inhibits FGFR1, FGFR2, and FGFR3 with IC\textsubscript{50} values of 0.9 nM, 1.4 nM, and 1 nM respectively in vitro evaluation. [1] BGJ398 also inhibits FGFR4, VEGFR2, Abl, Fyn, Kit, Lck, Lyn and Yes, with significantly lower potencies. In an in vivo test, BGJ398 showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. [1]

BGJ398 is currently being tested in a Phase II clinical trial in advanced cholangiocarcinoma (CCA) patients with FGFR genetic alterations for anti-tumor activity and safety profile. [2] [3]

### Reference:

   Pubmed ID: 21936542
2. https://clinicaltrials.gov/show/NCT02150967
   Pubmed ID: NCT02150967


For Technical Support:  [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*